Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Impact of Postoperative Complications in High-Risk Operable Non-small Cell Lung Cancer

  • Lee, Seungwook (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Roknuggaman, Md (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Son, Jung A (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Hyun, Seungji (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Jung, Joonho (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Haam, Seokjin (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine) ;
  • Yu, Woo Sik (Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine)
  • Received : 2021.09.03
  • Accepted : 2021.11.06
  • Published : 2022.02.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Patients with high-risk (HR) operable non-small cell lung cancer (NSCLC) may have unique prognostic factors. This study aimed to evaluate surgical outcomes in HR patients and to investigate prognostic factors in HR patients versus standard-risk (SR) patients. Methods: In total, 471 consecutive patients who underwent curative lung resection for NSCLC between January 2012 and December 2017 were identified and reviewed retrospectively. Patients were classified into HR (n=77) and SR (n=394) groups according to the American College of Surgeons Oncology Group criteria (Z4099 trial). Postoperative complications were defined as those of grade 2 or higher by the Clavien-Dindo classification. Results: The HR group comprised more men and older patients, had poorer lung function, and had more comorbidities than the SR group. The patients in the HR group also experienced more postoperative complications (p≤0.001). More HR patients died without disease recurrence. The postoperative complication rate was the only significant prognostic factor in multivariable Cox regression analysis for HR patients but not SR patients. HR patients without postoperative complications had a survival rate similar to that of SR patients. Conclusion: The overall postoperative survival of HR patients with NSCLC was more strongly affected by postoperative complications than by any other prognostic factor. Care should be taken to minimize postoperative complications, especially in HR patients.

Keywords

References

  1. Hong S, Won YJ, Park YR, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-50. https://doi.org/10.4143/crt.2020.206
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80. https://doi.org/10.1056/NEJMra0802714
  4. National Comprehensive Cancer Network. NCCN guidelines for non-small cell lung cancer, version 5.2021 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2021 [cited 2021 Aug 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  5. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801. https://doi.org/10.1097/jto.0b013e3181a7716e
  6. Yang CC, Fong Y, Lin LC, et al. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. Eur J Cardiothorac Surg 2018;53:235-40. https://doi.org/10.1093/ejcts/ezx215
  7. Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005;28:759-62. https://doi.org/10.1016/j.ejcts.2005.06.046
  8. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Moller H. The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur J Cancer 2012;48:3386-95. https://doi.org/10.1016/j.ejca.2012.06.012
  9. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 2004;57:597-609. https://doi.org/10.1016/j.jclinepi.2003.11.002
  10. Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest 2012;142:1620-35. https://doi.org/10.1378/chest.12-0790
  11. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):161S-177S. https://doi.org/10.1378/chest.07-1359
  12. Donahoe LL, de Valence M, Atenafu EG, et al. High risk for thoracotomy but not thoracoscopic lobectomy. Ann Thorac Surg 2017;103:1730-5. https://doi.org/10.1016/j.athoracsur.2016.11.076
  13. Fernando HC, Timmerman R. American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2012;144:S35-8. https://doi.org/10.1016/j.jtcvs.2012.06.003
  14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. https://doi.org/10.1016/0021-9681(87)90171-8
  15. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39-51. https://doi.org/10.1016/j.jtho.2015.09.009
  16. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96. https://doi.org/10.1097/SLA.0b013e3181b13ca2
  17. Puri V, Crabtree TD, Bell JM, et al. National cooperative group trials of "high-risk" patients with lung cancer: are they truly "high-risk"? Ann Thorac Surg 2014;97:1678-85. https://doi.org/10.1016/j.athoracsur.2013.12.028
  18. Taylor MD, LaPar DJ, Isbell JM, Kozower BD, Lau CL, Jones DR. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2014;147:738-46. https://doi.org/10.1016/j.jtcvs.2013.09.064
  19. Lugg ST, Agostini PJ, Tikka T, et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax 2016;71:171-6. https://doi.org/10.1136/thoraxjnl-2015-207697
  20. Puri V, Patel AP, Crabtree TD, et al. Unexpected readmission after lung cancer surgery: a benign event? J Thorac Cardiovasc Surg 2015;150:1496-505. https://doi.org/10.1016/j.jtcvs.2015.08.067
  21. Geraci TC, Ng T. When is it safe to operate for lung cancer?: selection of fiscally responsible cardiopulmonary function tests for limited resection (wedge resection and segmentectomy), standard lobectomy, sleeve lobectomy, and pneumonectomy. Thorac Surg Clin 2021;31:255-63. https://doi.org/10.1016/j.thorsurg.2021.04.006
  22. Bibo L, Goldblatt J, Merry C. Does preoperative pulmonary rehabilitation/physiotherapy improve patient outcomes following lung resection? Interact Cardiovasc Thorac Surg 2021;32:933-7. https://doi.org/10.1093/icvts/ivab011
  23. Kong M, Zheng H, Ding L, et al. Perioperative pulmonary rehabilitation training (PPRT) can reduce the cost of medical resources in patients undergoing thoracoscopic lung cancer resection: a retrospective study. Ann Palliat Med 2021;10:4418-27. https://doi.org/10.21037/apm-21-478
  24. Wang X, Wang N, Wang X, et al. Application value of goal-directed fluid therapy with ERAS in patients undergoing radical lung cancer surgery. Am J Transl Res 2021;13:8186-92.